Syndax Pharmaceuticals has been granted a patent for inhibitors targeting the interaction of menin with MLL and MLL fusion proteins, for treating cancer and other diseases. Claim 1 specifically covers compounds of Formula 0. GlobalData’s report on Syndax Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Syndax Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Syndax Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syndax Pharmaceuticals's grant share as of April 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11919901B2) discloses a compound of Formula 0, with various specific embodiments outlined in the claims. The compound is designed for the treatment of leukemia, particularly targeting the interaction between menin and MLL. The patent covers the use of the compound in pharmaceutical compositions and methods for inhibiting the interaction between menin and MLL, as well as treating leukemia in patients. The compound is described as minimizing hERG binding, which is crucial for its therapeutic effectiveness in leukemia treatment.

Furthermore, the patent details the specific chemical structure and variations of the compound, including different substituents and functional groups, to optimize its efficacy in treating leukemia. The compound is intended for use in various types of leukemia, such as mixed lineage leukemia (MLL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and other related forms of the disease. Additionally, the patent highlights the potential application of the compound in preventing diseases associated with menin expression, activity, and function, emphasizing its role in targeting specific molecular pathways involved in leukemia development. Overall, the patent provides a comprehensive framework for utilizing the compound in the treatment and prevention of leukemia and related conditions, showcasing its potential as a valuable therapeutic agent in the field of oncology.

To know more about GlobalData’s detailed insights on Syndax Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies